Jaguar health adopts limited duration stockholder rights plan to ensure stockholders can realize long-term value

Jaguar expects first results in q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease fda meeting expected in q2 2025 on the statistically significant results of the phase 3 ontarget trial of crofelemer in the prespecified subgroup of patients with breast cancer jaguar has received an indication of interest to acquire the company san francisco, ca / access newswire / february 27, 2025 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that its board of directors (the "board") has adopted a limited duration stockholder rights plan (the "rights plan"). "jaguar, which, like many other biotechnology companies, continues to experience a significant and ongoing dislocation in the trading price of its common stock, has received an indication of interest to acquire the company.
JAGX Ratings Summary
JAGX Quant Ranking